| 51 |
32099073 | Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis - A systematic analysis of 204 cases. | 2020 Feb 25 |
1 |
| 52 |
32116712 | Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib. | 2020 |
1 |
| 53 |
32198455 | Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells. | 2020 Mar 20 |
2 |
| 54 |
32291709 | Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors. | 2020 Sep |
2 |
| 55 |
32350132 | Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors. | 2020 Apr 29 |
2 |
| 56 |
32371592 | Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor. | 2020 Jun |
3 |
| 57 |
32457834 | Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report. | 2020 |
1 |
| 58 |
32560620 | Encapsulation of Imatinib in Targeted KIT-5 Nanoparticles for Reducing its Cardiotoxicity and Hepatotoxicity. | 2020 |
1 |
| 59 |
32615108 | Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. | 2020 Jul |
1 |
| 60 |
32619820 | Prognostic Indicators for Gastrointestinal Stromal Tumors: A Review. | 2020 Oct |
1 |
| 61 |
32640452 | An Unexpected Response to Imatinib in a "Wild-Type" Gastrointestinal Stromal Tumor. | 2020 |
1 |
| 62 |
32697050 | Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors. | 2020 Sep |
3 |
| 63 |
32753885 | Chloroquine Combined with Imatinib Overcomes Imatinib Resistance in Gastrointestinal Stromal Tumors by Inhibiting Autophagy via the MAPK/ERK Pathway. | 2020 |
1 |
| 64 |
32836055 | BRAF mutations in KIT/PDGFRA positive gastrointestinal stromal tumours (GISTs): Is their frequency underestimated? | 2020 Nov |
1 |
| 65 |
32843387 | Chronic mast cell leukaemia with exon 9 KIT mutation A502_Y503dup: a rare imatinib responsive variant. | 2020 Aug 24 |
1 |
| 66 |
32999756 | Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance. | 2020 |
1 |
| 67 |
33024275 | The V654A second-site KIT mutation increases tumor oncogenesis and STAT activation in a mouse model of gastrointestinal stromal tumor. | 2020 Dec |
2 |
| 68 |
33116851 | Abnormal MGMT Promoter Methylation in Gastrointestinal Stromal Tumors: Genetic Susceptibility and Association with Clinical Outcome. | 2020 |
1 |
| 69 |
33195674 | Gastrointestinal stromal tumor metastasis at the site of a totally implantable venous access port insertion: A rare case report. | 2020 Oct 26 |
1 |
| 70 |
33212994 | A Novel Kindred with Familial Gastrointestinal Stromal Tumors Caused by a Rare KIT Germline Mutation (N655K): Clinico-Pathological Presentation and TKI Sensitivity. | 2020 Nov 17 |
2 |
| 71 |
33468755 | [A Case of a Huge Gastrointestinal Stromal Tumor with Extraluminal Growth Arising in the Small Intestine Diagnosed as an Ovarian Tumor]. | 2020 Dec |
1 |
| 72 |
28777148 | New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs. | 2019 Jan |
1 |
| 73 |
30075827 | Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study. | 2019 Mar 29 |
2 |
| 74 |
30079802 | Hepatitis B virus reactivation following imatinib therapy: A comparative review of 9 cases. | 2019 Sep |
1 |
| 75 |
30126859 | Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib. | 2019 May |
1 |
| 76 |
30199578 | Successful treatment of metastatic mucosal melanoma with a Del579 c-KIT mutation by imatinib after treatment of anti-PD-1 antibody. | 2019 Mar |
1 |
| 77 |
30523507 | PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors. | 2019 May |
1 |
| 78 |
30530703 | Anagrelide for Gastrointestinal Stromal Tumor. | 2019 Mar 1 |
1 |
| 79 |
30536695 | Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. | 2019 Mar |
1 |
| 80 |
30569109 | Imatinib‑induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress. | 2019 Mar |
1 |
| 81 |
30612056 | Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis. | 2019 Feb |
1 |
| 82 |
30614559 | Response to imatinib in vaginal melanoma with KIT p.Val559Gly mutation previously treated with nivolumab, pembrolizumab and ipilimumab. | 2019 Jun |
1 |
| 83 |
30684595 | Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models. | 2019 Apr 10 |
3 |
| 84 |
30697609 | Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors. | 2019 Jan |
2 |
| 85 |
30707374 | KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development. | 2019 Jun |
1 |
| 86 |
30792533 | Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. | 2019 Mar |
4 |
| 87 |
30864679 | [Corrigendum] Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression. | 2019 May |
1 |
| 88 |
30880826 | Female Adnexal Tumour of Probable Wolffian Origin (FATWO): Review of the Literature. | 2019 Mar |
1 |
| 89 |
30902661 | Expanding spectrum of anticancer drug, imatinib, in the disorders affecting brain and spinal cord. | 2019 May |
1 |
| 90 |
30984366 | Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry. | 2019 |
1 |
| 91 |
31037149 | Repurposing Ponatinib as a Potent Agent against KIT Mutant Melanomas. | 2019 |
3 |
| 92 |
31043947 | Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I. | 2019 Jan-Apr |
3 |
| 93 |
31046271 | Discovery of ( E)- N1-(3-Fluorophenyl)- N3-(3-(2-(pyridin-2-yl)vinyl)-1 H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). | 2019 May 23 |
1 |
| 94 |
31083182 | Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib: A systematic review. | 2019 May |
1 |
| 95 |
31138788 | A juxtacrine/paracrine loop between C-Kit and stem cell factor promotes cancer stem cell survival in epithelial ovarian cancer. | 2019 May 28 |
1 |
| 96 |
31205499 | New frontiers in the medical management of gastrointestinal stromal tumours. | 2019 |
1 |
| 97 |
31205508 | Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors. | 2019 |
2 |
| 98 |
31236647 | Basic Knowledge in Soft Tissue Sarcoma. | 2019 Sep |
1 |
| 99 |
31308690 | Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategies. | 2019 |
2 |
| 100 |
31363162 | Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors. | 2019 Sep |
6 |